TABLE 1.
Characteristics of patients
| Characteristics | Formula establishment a (Previous study) | Prospective evaluation (This study) |
|---|---|---|
| Number | 16 | 30 |
| CLcr, mL/min | ||
| Median (range) | 63.0 (15.9‐108.8) | 51.4 (23.8‐96.4) |
| BSA, m2 | ||
| Median (range) | 1.66 (1.18‐2.02) | 1.52 (1.14‐1.84) |
| Sex | ||
| Male | 11 | 23 |
| Female | 5 | 7 |
| Age, y | ||
| Median (range) | 65.5 (45‐78) | 74.5 (52‐92) |
| Serum creatinine, mg/dL | ||
| Median (range) | 1.01 (0.48‐1.66) | 0.89 (0.52‐1.39) |
| Height, cm | ||
| Median (range) | 167.5 (148.0‐177.4) | 160.8 (139.9‐181.4) |
| Weight, kg | ||
| Median (range) | 56.3 (30.2‐87.0) | 51.3 (32.7‐70.9) |
| ECOG performance status | ||
| 0 | 12 | 18 |
| 1 | 2 | 12 |
| 2 | 2 | 0 |
| Cancer type | ||
| Gastric | 11 | 11 b |
| Pancreatic | 0 | 9 b |
| Esophagus | 0 | 6 |
| Esophagogastric | 0 | 3 |
| Lung | 2 | 1 |
| Biliary tract | 1 | 1 |
| Colorectal | 1 | 0 |
| Thymic | 1 | 0 |
| Gastrectomy | ||
| Yes | 9 | 12 |
| No | 7 | 18 |
| Chemotherapy setting | ||
| Adjuvant | 7 | 16 |
| Advanced | 9 | 14 |
Abbreviations: BSA, body surface area; CLcr, creatinine clearance estimated by the Cockcroft‐Gault equation.
a
Pharmacokinetic sampling times were before and 1, 2, 4, 7, 12, and 24 h after administration of S‐1.
b
One patient had double cancer of stomach and pancreas.